Clinical Trial Details

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and in Oncotype Recurrence Score = 25 (OFSET)

IRB Protocol Number

NRG BR009

Clinical Trial Categories

• Breast Cancer

How to Participate

Eligibility: 

Women ages 18 or older, diagnosed with ER and/or PR positive and HER2 negative breast cancer, with postoperative clinical staging pT1-3 pN0-1, meeting premenopausal criteria, with "Low Risk" result on MammaPrint® testing (to be tested if not performed prior).